Cancer Diagnosis Segment by Application to Account Larger Share in Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market during 2022–2030
According to our latest study on “Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis" the market is expected to grow from US$ 1,084.0 million in 2022 and is expected to reach US$ 1,901.4 million by 2030; it is anticipated to record a CAGR of 7.3% from 2022 to 2030. The report highlights the key factors driving the fluorescence in-situ hybridization (FISH) imaging systems market growth and prominent players with their developments in the market.
Fluorescence in situ hybridization (FISH) is a molecular technique for cytogenetic analysis. This technique uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. FISH detects the presence or absence of specific DNA sequences on chromosomes. FISH is often used to find specific features in DNA/RNA targets for medicine, genetic counseling, and species identification.
The fluorescence in-situ hybridization (FISH) imaging systems market, by product, is segmented into instruments, consumables, accessories, and software. The consumables segment held a larger market share in 2022 and same segment is anticipated to register a higher CAGR. Based on application, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnosis, and others. The cancer diagnosis segment held a larger market share in 2022 and same segment is anticipated to register a higher CAGR. FISH technology has tremendously benefited cancer diagnosis. FISH imaging systems can look for gene changes and help detect anomalies. According to Cancer Research UK, FISH testing is used for the diagnosis of several cancers, including breast cancer, lymphoma, lung cancer, prostate cancer, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myeloma, Ewings sarcoma, and melanoma skin cancer. Based on end user, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organization, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held a larger market share in 2022 and same segment is anticipated to register a higher CAGR.
Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc are among the leading companies operating in the global Fluorescence In-Situ Hybridization (FISH) Imaging Systems market.
Companies operating in the fluorescence in-situ hybridization (FISH) imaging systems market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the fluorescence in-situ hybridization (FISH) imaging systems market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall fluorescence in-situ hybridization (FISH) imaging systems market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com